STORM Therapeutics is developing first-in-class small molecule therapies that target RNA modifying enzymes (RME) to create novel cancer treatments. By focusing on over 150 RNA modifications and approximately 300 RNA modifying enzymes, the company aims to address the limitations of current cancer therapies.
Funding
$30M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CITVFounders
Product
Problem
Current cancer therapies face limitations in addressing the complex mechanisms of tumor development and resistance. Many existing treatments do not effectively target the underlying processes driven by RNA modifications, leaving a significant unmet need for novel therapeutic approaches.
Solution
STORM Therapeutics is developing a new class of small molecule therapies that target RNA modifying enzymes (RMEs). These enzymes play a crucial role in RNA modifications, which influence cellular decision-making and protein synthesis. By inhibiting specific RMEs, STORM aims to disrupt cancer progression and overcome resistance mechanisms. Their approach focuses on a wide range of RNA modifications and enzymes to identify promising drug targets for oncology and other diseases.
Target Audience
The primary target audience includes cancer patients who are not responding to existing therapies, as well as pharmaceutical companies seeking novel oncology drug candidates.
Features
- Development of first-in-class small molecule inhibitors of RNA modifying enzymes.
- Focus on over 150 RNA modifications and approximately 300 RNA modifying enzymes as therapeutic targets.
- STC-15: A METTL3 inhibitor in Phase 1 clinical trials.
- Targeting RNA modifications to modulate cellular processes relevant to cancer development.